Assessment of type I interferon response in routine practice in France in 2022.
Autoimmune Diseases
Cytokines
Dermatomyositis
Lupus Erythematosus, Systemic
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
04
04
2023
accepted:
22
05
2023
medline:
19
6
2023
pubmed:
16
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France.
Identifiants
pubmed: 37321666
pii: rmdopen-2023-003211
doi: 10.1136/rmdopen-2023-003211
pmc: PMC10277519
pii:
doi:
Substances chimiques
Interferon Type I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
RMD Open. 2023 Mar;9(1):
pubmed: 36863752
Cytokine. 2019 Jan;113:446-452
pubmed: 30413290
Ann Rheum Dis. 2023 Jun;82(6):754-762
pubmed: 36858821
Ann Rheum Dis. 2022 Dec;81(12):1695-1703
pubmed: 35973806
Clin Chem. 2020 Jun 1;66(6):802-808
pubmed: 32359149
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Ann Rheum Dis. 2022 Jun;81(6):901-903
pubmed: 35091421
RMD Open. 2023 Mar;9(1):
pubmed: 36882218
J Clin Immunol. 2017 Feb;37(2):123-132
pubmed: 27943079
J Exp Med. 2017 May 1;214(5):1547-1555
pubmed: 28420733
Hum Genomics Proteomics. 2009 Nov 17;2009:
pubmed: 20948567
Lancet Neurol. 2013 Dec;12(12):1159-69
pubmed: 24183309